US Continuous Glucose Monitoring Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Historical Data Period | 2019 - 2022 |
| CAGR | 9.60 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
US Continuous Glucose Monitoring Market Analysis
The United States Continuous Glucose Monitoring Market is expected to register a CAGR of 9.6% over the forecast period.
During the COVID-19 pandemic, patients with diabetes were at higher risk for hospitalizations and complications due to hyper- or hypoglycemia, metabolic comorbidities, and more severe illness from SARS-CoV-2 infection. The maintenance of euglycemia was important to decrease both morbidity and mortality in the hospital setting. The Food and Drug Administration (FDA) allowed the use of CGM devices in the inpatient setting in response to the COVID-19 pandemic. According to experts, inpatient use of diabetes technology in patients with proper institutional protocols was safe and improved inpatient glycemic outcomes and played a vital role in managing hypoglycemia and hyperglycemia in hospitalized patients.
Appropriate and timely monitoring of blood glucose allows the successful management of out-of-range blood glucose levels, minimizing diabetic-related health complications. Continued elevation in blood glucose levels in diabetes patients can contribute to progressive complications such as renal, nerve, and ocular damage. The measurement of blood glucose helps in determining the effectiveness of blood glucose metabolism and guides in achieving optimal glucose control within the body. Over time the readings provide the patient and their health professionals with the information required to determine the best management strategy for diabetes.
According to National Centre for Health Statistics, about 32.8% of adults aged 18 and over had obesity in 2021 in the United States. In obese individuals, the fat cells in the body release pro-inflammatory chemicals, which may make the body less sensitive to the insulin it produces by disrupting the function of insulin-responsive cells. Thus, these individuals need external insulin shots and are obligated to use a Continuous Glucose Monitoring device.
Furthermore, the current continuous glucose Monitoring can either retrospectively display the trends in the levels of blood glucose by downloading the data or give a real-time picture of glucose levels through receiver displays. The newest CGM models, the Abbott Freestyle Libre 3 and the Dexcom G7, overcame many technical barriers. Technological advances such as Eversense E3 CGMs have significantly improved the ability of providers and patients to manage diabetes, thereby enhancing the market prospects in the years to come.
US Continuous Glucose Monitoring Market Trends
Rising Diabetes Prevalence in the United States
The diabetes population in the United States is expected to rise by about 1.9% over the forecast period. In the United States, the prevalence of diabetes has increased dramatically during the last two decades, a fact driven by the increased prevalence of obesity and lifestyle changes owing to less physical activity, unhealthy food habits, and other lifestyle factors.
The Centers for Disease Control and Prevention (CDC) National Diabetes Statistics Report 2022 estimated that more than 130 million adults are living with diabetes or prediabetes in the United States. Type 2 diabetes is more common, and diabetes is more consequential among communities of color; those who live in rural areas; and those with less education, lower incomes, and lower health literacy.
The American Diabetes Association (ADA), the Endocrine Society, the American College of Physicians, the American Academy of Pediatrics, the Society of General Internal Medicine, and the National Academy of Medicine published statements and issued calls to action to address social determinants of health (SDOH) at the individual, organizational, and policy levels. In 2021, ADA also published a scientific review describing the associations between SDOH and diabetes risk and outcomes focusing on socioeconomic status, health literacy, the food environment, food insecurity, and neighborhood and physical environments, among other topics.
The World Health Assembly Resolution 2022 recommends the integration of prevention and treatment of diabetes into primary health services, the development of pathways for a substantial increase in access to insulin, the promotion of convergence and harmonization of regulatory requirements for diabetes medicines and technologies, and improved diabetes monitoring and surveillance. Furthermore, it involves the WHO to advise the Member States to ensure the uninterrupted treatment of people living with diabetes in humanitarian emergencies. This important milestone provides a global mandate for diabetes efforts for the next decade.
Therefore, the studied market is anticipated to witness growth over the analysis period due to rising prevalence and the aforementioned factors.
The sensors segment is expected to witness the highest growth rate over the forecast period
The Sensors Segment is expected to grow at a CAGR of about 9.2% over the forecast period.
Continuous glucose monitoring sensors use glucose oxidase to detect blood sugar levels. Glucose oxidase converts glucose to hydrogen peroxidase, which reacts with the platinum inside the sensor, producing an electrical signal to be communicated to the transmitter. Sensors are the most important part of continuous glucose Monitoring. Technological advancements to improve the accuracy of the sensors are expected to drive segment growth during the forecast period.
Researchers are trying to find and develop alternatives to electrochemical-based glucose sensors and create more affordable, minimally invasive, and user-friendly CGM sensors. Optical measurement is a promising platform for glucose sensing. Some technologies have been reported with high potential in continuous glucose sensing, including spectroscopy, fluorescence, holographic technology, etc. Eversense, a CGM sensor based on fluorescence sensing developed by Senseonics Company, presents a much longer lifespan in comparison with electrochemical sensors.
According to the Centre for Health Care Strategies for Medicaid agencies that can cover and increase access to CGMs for their beneficiaries and the larger healthcare system, there is strong evidence that supports the benefits of CGM use for all people who are insulin-treated with an insulin pump or multiple daily insulin injections, and emerging evidence show the benefit of CGMs in patients on basal insulin.
The aforementioned factors are set to boost market growth.
US Continuous Glucose Monitoring Industry Overview
The United States Continuous Glucose Monitoring Market is consolidated, with few significant players. The mergers and acquisitions between the players, like the acquisition of TypeZero Technologies by Dexcom, have sent Dexcom ahead on its way in the race to create an artificial pancreas system rather than merely offering a boost to the continuous glucose monitoring market. There have been constant innovations driven by manufacturers such as Abbott and Medtronic while also adhering to organic growth strategies, which is evident from the R&D spending of these companies.
US Continuous Glucose Monitoring Market Leaders
-
Abbott Diabetes Care
-
Dexcom Inc.
-
Ascensia Diabetes Care
-
Medtronic
-
GlySens
*Disclaimer: Major Players sorted in no particular order
US Continuous Glucose Monitoring Market News
- December 2022: Dexcom announced the FDA approval for their next-generation product, the Dexcom G7 CGM. The G7 is approved for people with all types of diabetes ages two years and older.
- October 2022: Abbott announced that the Freestyle Libre 3 is now available in pharmacies nationwide after it received FDA clearance in May 2022.
Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
- 4.2 Market Drivers
- 4.3 Market Restraints
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Bargaining Power of Suppliers
- 4.4.2 Bargaining Power of Consumers
- 4.4.3 Threat of New Entrants
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
-
5.1 Component
- 5.1.1 Sensors
- 5.1.2 Durables
6. MARKET INDICATORS
- 6.1 Type-1 Diabetes Population
- 6.2 Type-2 Diabetes Population
7. COMPETITIVE LANDSCAPE
-
7.1 Company Profiles
- 7.1.1 Abbott Diabetes Care
- 7.1.2 Dexcom Inc.
- 7.1.3 Medtronic PLC
- 7.1.4 Ascensia Diabetes Care
- 7.1.5 Eversense
- 7.1.6 GlySens
- *List Not Exhaustive
-
7.2 Company Share Analysis
- 7.2.1 Abbott Diabetes Care
- 7.2.2 Dexcom Inc.
- 7.2.3 Medtronic PLC
- 7.2.4 Others
8. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityUS Continuous Glucose Monitoring Industry Segmentation
Achieving optimum glycemic results can be very difficult without frequent monitoring of blood glucose levels. A continuous glucose monitor tracks blood sugar levels 24 hours a day. It collects readings automatically every five to 15 minutes and detects trends and patterns to provide a complete picture of diabetes. The United States Continuous Glucose Monitoring Market is segmented into Components (Sensors and Durables (Receivers and Transmitters)). The report offers the value (in USD million) and volume (in Units million) for the above segments.
| Component | Sensors |
| Durables |
Frequently Asked Questions
What is the current US Continuous Glucose Monitoring Market size?
The US Continuous Glucose Monitoring Market is projected to register a CAGR of 9.60% during the forecast period (2024-2029)
Who are the key players in US Continuous Glucose Monitoring Market?
Abbott Diabetes Care, Dexcom Inc., Ascensia Diabetes Care, Medtronic and GlySens are the major companies operating in the US Continuous Glucose Monitoring Market.
What years does this US Continuous Glucose Monitoring Market cover?
The report covers the US Continuous Glucose Monitoring Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the US Continuous Glucose Monitoring Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
US Continuous Glucose Monitoring Industry Report
Statistics for the 2024 US Continuous Glucose Monitoring market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. US Continuous Glucose Monitoring analysis includes a market forecast outlook to for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
